Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03304470
Other study ID # ATx201-003
Secondary ID
Status Completed
Phase Phase 2
First received September 25, 2017
Last updated March 19, 2018
Start date September 25, 2017
Est. completion date March 5, 2018

Study information

Verified date March 2018
Source AntibioTx A/S
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 2, 3-week, single-center, double-blind, randomized, two-arm, vehicle controlled study, with each individual receiving both active and vehicle treatment. Approximately 30 subjects with moderate atopic dermatitis will receive topically applied ATx201 CREAM 2% and matching vehicle once daily for 3 weeks (5 mg/cm2/day), without occlusion. ATx201 and vehicle will be applied on two separate target lesions of moderate atopic dermatitis (lesions of at least 3 × 3 cm, excluding the face, scalp, genitals, hands, and feet, ideally from the same anatomical location).


Recruitment information / eligibility

Status Completed
Enrollment 31
Est. completion date March 5, 2018
Est. primary completion date March 5, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- clinically confirmed diagnosis of active atopic dermatitis

- at least a 6-month history of atopic dermatitis and had no significant flares in atopic dermatitis for at least 4 weeks before screening

- =2 areas of atopic dermatitis (excluding face, scalp, genitals, hands, and feet) of at least 3 × 3 cm; with a lesional TSS of =5 at Day 1 for each treatment area

Exclusion Criteria:

- breastfeeding, pregnant, or is planning to become pregnant during the study.

- clinically infected atopic dermatitis

- Fitzpatrick's Skin Phototype =5

- Presence of any tattoos, scratches, open sores, excessive hair, or skin damages in the target lesion areas

- known to have immune deficiency or is immunocompromised.

- history of cancer or lymphoproliferative disease within 5 years prior to Day 1.

- major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the study.

- clinically significant medical condition or physical/laboratory/vital signs abnormality that would, in the opinion of the investigator, put the subject at undue risk or interfere with interpretation of study results.

- known history of chronic infectious disease (e.g., hepatitis B, hepatitis C, or infection with human immunodeficiency virus).

- used hydroxyzine or diphenhydramine within 1 week prior to Day 1.

- used dupilumab within 12 weeks prior to Day 1.

- received any nonbiological investigational product or device within 4 weeks prior to Day 1

- used crisaborole and any other topical PDE-4 inhibitor within 4 weeks prior to Day 1.

- used doxepin within 1 week prior to Day 1.

- used topical products containing urea within 1 week prior to Day 1.

- used nonurea-containing emollient anywhere on the body from 1 day before Day 1.

- used systemic antibiotics or topical antibiotics on the treated areas within 2 weeks prior to Day 1.

- used any topical medicated treatment for atopic dermatitis within 2 weeks prior to Day 1, including, but not limited to, topical corticosteroids, calcineurin inhibitors, tars, bleach, antimicrobials, medical devices, and bleach baths.

- used systemic treatments (other than biologics) that could affect atopic dermatitis less than 4 weeks prior to Day 1 (e.g., retinoids, calcineurin inhibitors, methotrexate, cyclosporine, hydroxycarbamide [hydroxyurea], azathioprine, oral/injectable corticosteroids).

- received any marketed or investigational biological agent within 12 weeks or 5 half-lives (whichever is longer) prior to Day 1.

- excessive sun exposure, is planning a trip to a sunny climate, has received ultraviolet phototherapy, or has used tanning booths within 4 weeks prior to Day 1, or is not willing to minimize natural and artificial sunlight exposure during the study. Use of sunscreen products (excluding the treatment areas) and protective apparel are recommended when exposure cannot be avoided.

- known or suspected allergy to ATx201 or any component of the investigational product.

- known history of clinically significant drug or alcohol abuse in the last year prior to Day 1.

- history of an allergic reaction or significant sensitivity to lidocaine or other local anesthetics.

- history of hypertrophic scarring or keloid formation in scars or suture sites.

- taking anticoagulant medication, such as heparin, low molecular weight-heparin, warfarin, or antiplatelets (nonsteroidal anti-inflammatory drugs and aspirin =81 mg will not be considered antiplatelets) within 2 weeks prior to Day 1, or has a contraindication to skin biopsies.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ATx201 2% Cream
Anhydrous Cream
ATx201 Cream Vehicle
Anhydrous Cream

Locations

Country Name City State
Canada Innovaderm Research Inc Montréal Quebec

Sponsors (1)

Lead Sponsor Collaborator
AntibioTx A/S

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of local and systemic treatment-emergent adverse events # of TEAEs 34 days
Secondary Change from baseline in lesional Total Sign Score at Days 8, 15, and 22. 22 Days
Secondary Change from baseline in lesional Treatment Areas Assessment at Days 8, 15, and 22 22 Days
Secondary Change from baseline in skin barrier and biomarker levels at Day 22 Day 22
See also
  Status Clinical Trial Phase
Completed NCT05018806 - Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis Phase 2
Completed NCT04090229 - A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis Phase 1
Terminated NCT03847389 - Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis Phase 1/Phase 2
Active, not recruiting NCT05388760 - Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1) Phase 2
Completed NCT05530707 - Evaluation of Acceptability, Skin Barrier Restoration and Balance of Atopic Skin Using Moisturizer N/A
Completed NCT02595073 - Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis Phase 3
Recruiting NCT05509023 - Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) Phase 2
Recruiting NCT05048056 - Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis Phase 2
Completed NCT04598269 - Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis Phase 2
Recruiting NCT03936335 - An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
Withdrawn NCT03089476 - Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy N/A
Recruiting NCT05029895 - A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
Terminated NCT03654755 - Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis Phase 2
Completed NCT04556461 - Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function Phase 2
Recruiting NCT04818138 - BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort N/A
Completed NCT03719742 - A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer N/A
Completed NCT05375955 - A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. Phase 2
Completed NCT03441568 - In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control N/A
Recruiting NCT06366932 - Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models Phase 4
Completed NCT04146363 - Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1) Phase 3